文献速递白血病造血干细胞移植与细胞治疗

KLF4-DYRK2通路调控CML干细胞自我更新

A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells.
PubMed 文献 · Blood · 2019-01-01

该研究在CML样骨髓增殖性肿瘤小鼠模型中发现,KLF4通过抑制Dyrk2基因促进白血病干/祖细胞自我更新;敲除Klf4损害BCR-ABL1+ CD150+ LSK细胞存活与自我更新;维生素K3抑制SIAH2稳定DYRK2,促进小鼠和人类CML干/祖细胞凋亡并消除自我更新。

要点

  • KLF4通过抑制Dyrk2维持CML干/祖细胞存活与自我更新。
  • Klf4缺失升高DYRK2,耗竭c-Myc并激活p53,损害白血病起始细胞。
  • 维生素K3抑制SIAH2稳定DYRK2,靶向清除小鼠和人类CML干/祖细胞。

核心结论

  • DYRK2是控制CML白血病起始细胞存活与自我更新的分子检查点,可被小分子靶向。

研究设计与样本

  • 研究采用CML样骨髓增殖性肿瘤小鼠模型,结合Klf4基因敲除与BCR-ABL1(p210)诱导的白血病细胞分析。

主要发现

  • 敲除Klf4严重损害BCR-ABL1(p210)诱导CML的维持,削弱BCR-ABL1+ CD150+ lineage-negative Sca-1+ c-Kit+白血病细胞的存活与自我更新。
  • KLF4在白血病干/祖细胞中抑制Dyrk2基因,KLF4缺失导致DYRK2升高,通过耗竭c-Myc蛋白和激活p53抑制存活与自我更新。
  • 维生素K3抑制泛素E3连接酶SIAH2以稳定DYRK2蛋白,促进小鼠和人类CML干/祖细胞凋亡并消除自我更新。

临床怎么用

  • 提示靶向KLF4-DYRK2轴或使用维生素K3稳定DYRK2可能清除CML白血病起始细胞。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Leukemia stem cells are a rare population with a primitive progenitor phenotype that can initiate, sustain, and recapitulate leukemia through a poorly understood mechanism of self-renewal. Here, we report that Krüppel-like factor 4 (KLF4) promotes disease progression in a murine model of chronic myeloid leukemia (CML)-like myeloproliferative neoplasia by repressing an inhibitory mechanism of preservation in leukemia stem/progenitor cells with leukemia-initiating capacity. Deletion of the Klf4 gene severely abrogated the maintenance of BCR-ABL1(p210)-induced CML by impairing survival and self-renewal in BCR-ABL1+ CD150+ lineage-negative Sca-1+ c-Kit+ leukemic cells. Mechanistically, KLF4 repressed the Dyrk2 gene in leukemic stem/progenitor cells; thus, loss of KLF4 resulted in elevated levels of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2), which were associated with inhibition of survival and self-renewal via depletion of c-Myc protein and p53 activation. In addition to transcriptional regulation, stabilization of DYRK2 protein by inhibiting ubiquitin E3 ligase SIAH2 with vitamin K3 promoted apoptosis and abrogated self-renewal in murine and human CML stem/progenitor cells. Altogether, our results suggest that DYRK2 is a molecular checkpoint controlling p53- and c-Myc-mediated regulation of survival and self-renewal in CML cells with leukemic-initiating capacity that can be targeted with small molecules.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Park CS, Lewis AH, Chen TJ, et al. A KLF4-DYRK2-mediated pathway regulating self-renewal in CML stem cells. Blood. 2019. PMID: 31515251. doi:10.1182/blood.2018875922

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。